Statins and myopathy [7]

Lancet

Volumn 359, Issue 9307, 2002, Pages 711-712

  Hargreaves, Iain P ^a   Heales, Simon ^a  

^a National Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; GEMFIBROZIL; UBIDECARENONE; DRUG DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UBIQUINONE;

CLINICAL TRIAL; DRUG MEGADOSE; DRUG USE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; ENZYME REPLACEMENT; EXERCISE; HUMAN; HYPERLIPIDEMIA; LETTER; MITOCHONDRIAL RESPIRATION; MYOGLOBINURIA; OXIDATIVE PHOSPHORYLATION; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; RHABDOMYOLYSIS; BLOOD; CHEMICALLY INDUCED DISORDER; NOTE;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RHABDOMYOLYSIS; UBIQUINONE;

EID: 0037160587     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07795-4     Document Type: Letter

References (5)

1. Learning from the cerivastatin experience
2. 10 biosynthesis by lipid lowering HMG-CoA reductase inhibitors (statins): A critical overview
3. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy
4. 10) deficiency
5. Gemfibrozil-induced decrease in serum ubiquinone and alpha and gamma-tocopherol levels in men with combined hyperlipidaemia